How the human genome can predict response to Hepatitis C therapy

It has long been suspected that host genetic factors influenced treatment outcome of hepatitis C virus (HCV) infection. Three independent genome-wide association studies have recently identified genetic variation in the IL28B gene (coding for IFN-λ3) that determines the outcome of interferon-α-based therapy for patients with genotype 1 chronic hepatitis C infection. These discoveries confirm the potential for a pharmacogenomics approach to personalizing anti-HCV treatment


Published in:
Current Hepatitis Reports, 9, 1, 1-8
Year:
2010
Note:
Report
Laboratories:




 Record created 2011-04-19, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)